Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tachykinin receptor 3 (TACR3), also known as the neuromedin-K receptor or neurokinin-3 receptor (NK3R), is a G protein-coupled receptor (GPCR) belonging to the rhodopsin-like family. It is primarily activated by its high-affinity endogenous ligand, neurokinin B (NKB), and couples to the Gq/11 signaling pathway to stimulate phospholipase C activity and intracellular calcium mobilization.\n\nTACR3 is widely expressed in the central nervous system, particularly within the hypothalamus, where it plays a critical role in the regulation of gonadotropin-releasing hormone (GnRH) secretion, reproductive function, and body temperature homeostasis via kisspeptin/neurokinin B/dynorphin (KNDy) neurons. Dysregulation of the NKB/TACR3 pathway is heavily implicated in the pathophysiology of menopausal vasomotor symptoms (hot flashes and night sweats), where estrogen deficiency leads to hypertrophy of KNDy neurons and hyperactivation of TACR3-mediated thermoregulatory pathways. Additionally, genetic mutations in TACR3 are associated with congenital hypogonadotropic hypogonadism, and the receptor has been investigated in psychiatric conditions such as schizophrenia and bipolar disorder. Pharmacological modulation of TACR3 has emerged as a major therapeutic strategy, highlighted by the FDA approval of fezolinetant (Veozah) and elinzanetant (Lynkuet) as non-hormonal treatments for menopausal hot flashes. These small-molecule antagonists block NKB binding to TACR3, thereby restoring normal thermoregulation in the hypothalamus. However, therapeutic targeting of TACR3 requires careful monitoring due to safety concerns, most notably the risk of elevated liver transaminases and potential drug-induced liver injury, which necessitates routine hepatic function testing.
Antagonism of the neurokinin-3 receptor to block neurokinin B binding, thereby modulating hypothalamic thermoregulation and gonadotropin secretion.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tachykinin receptor 3 (TACR3).